Hepatogastroenterology Unit, Second Department of Internal Medicine and Research Institute, Attikon University General Hospital, Medical School, Athens University, Rimini 1, 124 62, Athens, Greece,
Dig Dis Sci. 2014 Sep;59(9):2207-14. doi: 10.1007/s10620-014-3135-1. Epub 2014 Apr 8.
Partially hydrolyzed guar gum (PHGG) is a water-soluble, non-gelling dietary fiber with a wide range of uses in clinical nutrition. The aim of this prospective study was to investigate the effect of guar gum on colonic transit time (CTT) and symptoms of chronic constipation.
We enrolled patients fulfilling Rome III criteria for chronic constipation. CTT was measured before and at the end of treatment. After a 2-week run-in period, patients received 5 mg PHGG daily for 4 weeks. During study period, patients kept daily symptoms, stool and laxative usage diaries. They also recorded their symptom-related satisfaction weekly and treatment adverse events.
Forty-nine patients received treatment; 39 (80 %) completed the study. Treatment significantly reduced colon transit time, from 57.28 ± 39.25 to 45.63 ± 37.27 h (p = 0.026), a reduction more prominent in slow transit patients (from 85.50 ± 27.75 to 63.65 ± 38.11 h, p = 0.016). Overall, the weekly number of complete spontaneous and spontaneous bowel movements increased significantly (p < 0.001); the latter correlated significantly with the acceleration of CTT in the overall population and in slow transit patients (B = 0.382; p = 0.016 and B = 0.483; p = 0.023, respectively). In addition, the number of bowel movements with straining decreased (p < 0.001) and stool form improved (p < 0.001), while days with laxative intake and days with abdominal pain decreased (p = 0.001 and p = 0.027, respectively).
Four-week PHGG use accelerates colon transit time in patients with chronic constipation, especially in those with slow transit, and improves many of their symptoms including frequency of bowel movements.
部分水解瓜尔胶(PHGG)是一种水溶性、非胶凝膳食纤维,在临床营养中有广泛的用途。本前瞻性研究的目的是研究瓜尔胶对结肠传输时间(CTT)和慢性便秘症状的影响。
我们纳入符合罗马 III 标准的慢性便秘患者。在治疗前和治疗结束时测量 CTT。在 2 周的导入期后,患者每天接受 5 毫克 PHGG 治疗 4 周。在研究期间,患者每天记录症状、粪便和泻药使用日记。他们还每周记录症状相关满意度和治疗不良反应。
49 名患者接受了治疗;39 名(80%)完成了研究。治疗显著缩短了结肠传输时间,从 57.28±39.25 小时降至 45.63±37.27 小时(p=0.026),在慢传输患者中更为明显(从 85.50±27.75 小时降至 63.65±38.11 小时,p=0.016)。总体而言,每周完全自发性和自发性排便次数明显增加(p<0.001);后者与总体人群和慢传输患者的 CTT 加速显著相关(B=0.382;p=0.016 和 B=0.483;p=0.023)。此外,用力排便的次数减少(p<0.001),粪便形态改善(p<0.001),而泻药摄入天数和腹痛天数减少(p=0.001 和 p=0.027)。
PHGG 使用 4 周可加速慢性便秘患者的结肠传输时间,尤其是在慢传输患者中,并改善他们的许多症状,包括排便频率。